

Intergroupe Francophone du Myélome/IFM

Publications 2021

[Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma \(CASSIOPEIA\): an open-label, randomized, phase 3 trial.](#)

Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Béné MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickenberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P.

Lancet Oncol. 2021 Sep 13:S1470-2045(21)00428-9. Doi: 10.1016/S1470-2045(21)00428-9. Online ahead of print

PMID: 3452993

[Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.](#)

Hulin C, Offner F, Moreau P, Roussel M, Belhadj K, Benboubker L, Caillot D, Facon T, Garderet L, Kuhnowski F, Stoppa AM, Kolb B, Tiab M, Jie KS, Westerman M, Lambert J, Pei L, Vanquickenberghe V, De Boer C, Vermeulen J, Kampfenkel T, Sonneveld P, Van de Donk NWCJ.

Haematologica. 2021 Mar 4. Doi: 10.3324/haematol.2020.261842. Online ahead of print

PMID: 33657786

[Del\(17p\) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.](#)

Corre J, Perrot A, Caillot D, Belhadj K, Hulin C, Leleu X, Mohty M, Facon T, Buisson L, Do Souto L, Lannes R, Dufrechou S, Prade N, Orsini-Piocelle F, Voillat L, Jaccard A, Karlin L, Macro M, Brechignac S, Dib M, Sanhes L, Fontan J, Clement-Filliatre L, Marolleau JP, Minvielle S, Moreau P, Avet-Loiseau H.

Blood. 2021 Mar 4;137(9):1192-1195. Doi: 10.1182/blood.2020008346

PMID: 33080624

[Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.](#)

Moreau P, Hebraud B, Facon T, Leleu X, Hulin C, Hashim M, Hu Y, Caillot D, Benboubker L, Zweegman S, Merz M, Weisel K, Salwender H, Mai EK, Goldschmidt H, Bertsch U, Vanquickenberghe V, Kampfenkel T, Boer C, Krotneva S, Proskorovsky I, He J, Lam A, Lee C, Cote S, Sonneveld P.

Immunotherapy. 2021 Feb;13(2):143-154. doi: 10.2217/imt-2020-0266. Epub 2020 Nov 24.

PMID: 33228440

[Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study](#)

Hulin C, Offner F, Moreau P, Roussel M, Belhadj K, Benboubker L, Caillot D, Facon T, Garderet L, Kuhnowski F, Stoppa AM, Kolb B, Tiab M, Jie KS, Westerman M, Lambert J, Pei L, Vanquickenberghe V, De Boer C, Vermeulen J, Kampfenkel T, Sonneveld P, Van de Donk NWCJ.

Haematologica. 2021 Mar 4. doi: 10.3324/haematol.2020.261842. Online ahead of print.

PMID: 33657786

[Del\(17p\) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma](#)

Corre J, Perrot A, Caillot D, Belhadj K, Hulin C, Leleu X, Mohty M, Facon T, Buisson L, Do Souto L, Lannes R, Dufrechou S, Prade N, Orsini-Piocelle F, Voillat L, Jaccard A, Karlin L, Macro M, Brechignac S, Dib M, Sanhes L, Fontan J, Clement-Filliatre L, Marolleau JP, Minvielle S, Moreau P, Avet-Loiseau H. d.

Blood. 2021 Mar 4;137(9):1192-1195. doi: 10.1182/blood.2020008346.

PMID: 33080624

[Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results.](#)

Roussel M, Lauwers-Cances V, Wuilleme S, Belhadj K, Manier S, Garderet L, Escoffre-Barbe M, Mariette C, Benboubker L, Caillot D, Sonntag C, Touzeau C, Dupuis J, Moreau P, Leleu X, Facon T, Hébraud B, Corre J, Attal M. *Blood*. 2021 Apr 7;blood.2021010744. doi: 10.1182/blood.2021010744. Online ahead of print. PMID: 33827114

[No survival improvement in patients with high-risk multiple myeloma harbouring del\(17p\) and/or t\(4;14\) over the two past decades](#)

Chalopin T, Vallet N, Theisen O, Ochmann M, Tiab M, Godmer P, Barin C, Hérault O, Gyan E, Le Gouill S, Avet-Loiseau H, Benboubker L, Moreau P, Touzeau C. *Br J Haematol*. 2021 Apr 29. doi: 10.1111/bjh.17488. Online ahead of print. PMID: 33928635

[Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma \(CASSIOPEIA\): an open-label, randomised, phase 3 trial.](#)

Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Béné MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickenberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P. *Lancet Oncol*. 2021 Sep 13:S1470-2045(21)00428-9. doi: 10.1016/S1470-2045(21)00428-9. Online ahead of print. PMID: 34529931

[Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.](#)

Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T; Intergroupe Francophone du Myelome Multiple (IFM), Leleu X. *Leukemia*. 2021 Oct 14. doi: 10.1038/s41375-021-01415-x. Online ahead of print. PMID: 34650225

[DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France](#)

Broussais F, Bay JO, Boissel N, Baruchel A, Arnulf B, Morschhauser F, Robin M, Guepin GR, Moreau P, Gandemer V, Manier S, Leguay T, Nguyen Quoc S, Schwartzmann A, Houot R, Le Gouill S. *Bull Cancer*. 2021 Oct;108(10S):S143-S154. doi: 10.1016/j.bulcan.2021.07.002. PMID: 34920797

[All-oral triplet combination with ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible myeloma patients: final results of the phase 2 IFM study 2013-06.](#)

Touzeau C, Perrot A, Roussel M, Karlin L, Benboubker L, Jacquet C, Mohty M, Facon T, Manier S, Chretien ML, Tiab M, Hulin C, Leleu X, Loiseau HA, Dejoie T, Planche L, Attal M, Moreau P. *Haematologica*. 2022 Feb 17. doi: 10.3324/haematol.2021.280394. Online ahead of print. PMID: 35172566

[Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.](#)

Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, Karlin L, Perrot A, Touzeau C, Chrétien ML, Rigaudeau S, Dib M, Nicolas-Virelizier E, Escoffre-Barbe M, Belhadj K, Mariette C, Stoppa AM, Araujo C, Doyen C, Fontan J, Kolb B, Garderet L, Brechignac S, Malfuson JV, Jaccard A, Lenain P, Borel C, Hébraud B, Benbrahim O, Dorvaux V, Manier S, Augeul-Meunier K, Vekemans MC, Randriamalala E, Chaoui D, Caers J, Chaletex C, Benboubker L, Vincent L, Glaisner S, Zunic P, Slama B, Eveillard JR, Humbrecht-Kraut C, Morel V, Mineur P, Eisenmann JC, Demarquette H, Richez V, Vignon M, Caillot D, Facon T, Moreau P, Colin AL, Olivier P, Wuilleme S, Avet-Loiseau H, Corre J, Attal M. *Blood*. 2022 May 5;139(18):2747-2757. doi: 10.1182/blood.2021014635. PMID: 35511184